Avoiding Iatrogenic Cushing's in Children on Hydrocortisone for Adrenal Androgen Excess
Use hydrocortisone 10-15 mg/m²/day divided into three daily doses, monitor closely for signs of glucocorticoid excess (growth suppression, weight gain, blood pressure elevation), and avoid attempting to completely normalize 17-OHP levels which invariably leads to overtreatment. 1
Dosing Strategy to Prevent Iatrogenic Cushing's
The fundamental challenge in treating congenital adrenal hyperplasia is balancing androgen suppression against hypercortisolism—undertreatment risks adrenal crisis and virilization, while overtreatment causes growth suppression, hypertension, and iatrogenic Cushing's syndrome 1.
Specific Dosing Parameters
- Start with 10-15 mg/m²/day of hydrocortisone tablets divided into three daily doses 1
- Never use oral hydrocortisone suspension or chronic long-acting potent glucocorticoids (prednisone, prednisolone, dexamethasone) in growing children—these have significantly higher risk of growth suppression 1
- Hydrocortisone is mandatory in childhood due to its short half-life, which minimizes adverse effects compared to longer-acting agents 1
Critical Dosing Pitfall
Do not attempt to completely normalize 17-OHP levels—this is the most common cause of iatrogenic Cushing's in CAH management. Attempts to fully suppress 17-OHP typically result in overtreatment 1. The cortisol concentration that inhibits 50% of 17-OHP synthesis is only 48.6 nmol/L, meaning even modest cortisol elevations will suppress androgens 2.
Monitoring Strategy
What to Monitor For
Signs of glucocorticoid excess:
- Growth velocity deceleration (most sensitive early indicator)
- Weight gain disproportionate to height
- Blood pressure elevation
- Cushingoid features (moon facies, striae, central adiposity)
Signs of inadequate suppression:
- Accelerated bone age advancement
- Rapid growth velocity (paradoxically)
- Progressive virilization
Monitoring Frequency
- Infancy requires frequent reassessment due to rapid changes in body surface area and metabolism 1
- During initial dose reduction from supraphysiologic levels, reassess every 2-4 weeks
- Once stable, monitor growth parameters every 3 months
- Annual bone age assessment
Tapering Strategy When Overtreatment Occurs
If iatrogenic Cushing's develops:
- Decrease the initial dose in small decrements at appropriate intervals until reaching the lowest dose maintaining adequate clinical response 3
- Gradual withdrawal is mandatory—abrupt discontinuation after long-term therapy can precipitate adrenal crisis and death 4
- Target the lower end of the dosing range (10 mg/m²/day rather than 15 mg/m²/day) 1
- Accept modestly elevated 17-OHP levels rather than pursuing complete normalization
Specific Tapering Approach
When reducing from excessive doses:
- Decrease by 10-20% every 1-2 weeks
- Monitor for signs of adrenal insufficiency (fatigue, hypotension, hypoglycemia)
- Watch for cortisol withdrawal syndrome even when doses remain supraphysiologic 4
- Consider switching to more frequent dosing (4 times daily) at lower total daily dose to maintain better physiologic coverage while reducing total exposure 2
Special Considerations
During illness or stress: Increase doses 2-3 fold for febrile illness >38.5°C, gastroenteritis with dehydration, surgery, or major trauma 1. Do NOT increase for emotional stress, minor illness, or exercise 1.
Puberty: Hydrocortisone clearance changes during puberty may necessitate dosing adjustments, but resist the temptation to escalate doses excessively 5.
Alternative regimens: While three-times-daily dosing is guideline-recommended, recent evidence suggests four-times-daily dosing (38% at 06:00,22% at 12:00,17% at 18:00,22% at 24:00) better mimics physiologic cortisol rhythm and may reduce total daily dose requirements 2. However, compliance becomes more challenging.
The key principle is that growth suppression is the price of overtreatment, and accepting biochemical imperfection (elevated 17-OHP) is preferable to creating iatrogenic Cushing's syndrome in a growing child 1.